Cardiovascular Systems Inc (CSII): Leslie Trigg , director of Cardiovascular Systems Inc sold 3,500 shares on Feb 3, 2015. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $33.86 per share for a total value of $118,516.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 25, 2016, Capital Management Llc Camber (10% owner) purchased 250,000 shares at $7.55 per share price.On Jan 25, 2016, Scott R. Ward (CEO) purchased 2,700 shares at $9.30 per share price.Also, On Oct 6, 2015, Robert J. Thatcher (Chief Healthcare Policy Off’r) sold 64,700 shares at $16.31 per share price.On Sep 3, 2015, Kevin J. Kenny (Chief Operating Officer) sold 5,289 shares at $23.85 per share price.
Cardiovascular Systems Inc: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Cardiovascular Systems Inc which led to swings in the share price. The shares opened for trading at $16.84 and hit $17.39 on the upside , eventually ending the session at $17.36, with a gain of 2.78% or 0.47 points. The heightened volatility saw the trading volume jump to 2,53,186 shares. The 52-week high of the share price is $32.91 and the company has a market cap of $567 M . The 52-week low of the share price is at $7.5.
Company has been under the radar of several Street Analysts.Cardiovascular Systems Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 20 from a previous price target of $16 .The Rating was issued on May 5, 2016.Cardiovascular Systems Inc is Upgraded by Needham to Buy and the brokerage firm has set the Price Target at $16. Earlier the firm had a rating of Underperform on the company shares. The Rating was issued on Apr 1, 2016.
Cardiovascular Systems Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee. Its products include Stealth 360 degree Peripheral Orbital Atherectomy System (OAS); the Diamondback 360 Peripheral OAS (Diamondback 360 Peripheral) and Diamondback 360 Peripheral Diamondback 360 60cm Peripheral OAS and Diamondback 360 4 French 1.25 Peripheral (collectively called as peripheral arterial disease systems (PAD systems)). Its coronary product the Diamondback 360 Coronary OAS (CAD System) is a catheter-based platform designed to facilitate stent delivery in patients with coronary arterial disease (CAD). The CAD System design is customized for the coronary application.